Labeling Kids Mentally Ill for Profit – E. Pringle Mon, 14 Mar 2005 Independent, investigative reporters in Texas, Illinois, Ohio, FloridaŠare questioning the rationale for the recommendations of President Bush’s New Freedom Commission on Mental Health report calling for universal screening for mental illness. These investigative reporter have discovered that…
FDA May Require Longer Studies Before Approving Psych Drugs – WSJ Tue, 18 Oct 2005 The Wall Street Journal reports that the FDA has sent out feelers to drug manufacturers to provide “longer-term efficacy data” for psychotropic drugs. This comes after a mountain of evidence shows placebo “works” just as…
Doctors Without Borders: Why you can’t trust medical journals anymore Tue, 13 Apr 2004 Related link: Hear an interview with Shannon Brownlee on NPR at: http://www.npr.org/features/feature.php?wfId=1874563 Doctors Without Borders in the Washington Monthly (excerpt below), looks at the intricate web of collaborating players in medicine who are financially tied one…
TONIGHT ABC “PRIMETIME LIVE” INVESTIGATION reveals evidence that drug makers suppressed antidepressant info Thu, 9 Dec 2004 At least 100 children have committed suicide while on an SSRI antidepressant, hundreds more have attempted suicide. Tonight at 10:00 PM, ABC Prime Time Live will reveal internal company documents that show how…
NIH Under Fire: Longtime Favorite of Congress – Wash Post / WSJ Sun, 27 Jun 2004 Under fire from Congress with evidence of NIH staff engaging in secret outside contracts and consultancies, NIH Director, Dr. Elias Zerhouni, turned a corner. He acknowledged the problem at a hearing (June 22) of…
Homeland Security bill – Pharma Immunity – WP Fri, 15 Nov 2002 The Homeland Security bill that passed the House includes sweeping last minute provisions attached to it that have nothing to do with the war on terrorism. The provisions put the interest of pharmaceutical industry giants above the health…
Superiority of Zyprexa (Olanzapine) Challenged Mon, 1 Dec 2003 “The profound issue in health care is do we pay anything — regardless of the price — for a statistically significant benefit?” A major 12 month randomized study compared the effectiveness and cost effectiveness of Eli Lilly’s $3.7 billion blockbuster schizophrenia…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I , Spring 2005 Mon, 29 Aug 2005 Some uncritical promoters of psychiatry and its current biological treatment paradigm have declared that the introduction…
How to earn promotions in pharmaceutical industry Tue, 6 Sep 2005 In the world of pharmaceuticals, careers are made by marketing the worst products that cause the greatest harm. Contact: Vera Hassner Sharav 212-595-8974 XenoPort Appoints Gary D. Tollefson, Former Lilly Executive, to Board Company Snapshot: XNPThttp://www.xenoport.com SANTA CLARA, Calif.,…
ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it…
Recycled drugs: failed antidepressants– Stratera marketed for ADHD; Cymbalta for incontinence Mon, 26 Apr 2004 A front page article in The Wall Street Journal (excerpt below) provides a roadmap of failed Eli Lilly drugs which the company repackaged for a different condition than the one for which the drugs had…
